Full Text:  <1009>

Suppl. Mater.: 

Summary:  <224>

CLC number: 

On-line Access: 2022-02-17

Received: 2021-04-25

Revision Accepted: 2021-08-30

Crosschecked: 0000-00-00

Cited: 0

Clicked: 1577

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Yin LI

https://orcid.org/0000-0002-4019-3391

Yi ZHANG

https://orcid.org/0000-0001-5875-6108

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B

Accepted manuscript available online (unedited version)


Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1


Author(s):  Chenxi GAO, Jinming SHI, Jingxin ZHANG, Yin LI, Yi ZHANG

Affiliation(s):  Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China; more

Corresponding email(s):  syzi@163.com, yinli@bjmu.edu.cn

Key Words:  Ovarian cancer; Intraperitoneal tumor microenvironment; Chemerin; Programmed death ligand 1 (PD-L1)


Share this article to: More <<< Previous Paper|Next Paper >>>

Chenxi GAO, Jinming SHI, Jingxin ZHANG, Yin LI, Yi ZHANG. Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1[J]. Journal of Zhejiang University Science B, 2022, 23(7): 164-170.

@article{title="Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1",
author="Chenxi GAO, Jinming SHI, Jingxin ZHANG, Yin LI, Yi ZHANG",
journal="Journal of Zhejiang University Science B",
volume="23",
number="2",
pages="164-170",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2100392"
}

%0 Journal Article
%T Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1
%A Chenxi GAO
%A Jinming SHI
%A Jingxin ZHANG
%A Yin LI
%A Yi ZHANG
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 2
%P 164-170
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer

TY - JOUR
T1 - Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1
A1 - Chenxi GAO
A1 - Jinming SHI
A1 - Jingxin ZHANG
A1 - Yin LI
A1 - Yi ZHANG
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 2
SP - 164
EP - 170
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -


Abstract: 
Ovarian cancer is the third-most-common malignant reproductive tumor in women. According to the American Cancer Society, it has the highest mortality rate of gynecological tumors. The five-year survival rate was only 29% during the period from 1975 to 2008 (Reid et al., 2017). In recent decades, the five-year survival rate of ovarian cancer has remained around 30% despite continuous improvements in surgery, chemotherapy, radiotherapy, and other therapeutic methods. However, because of the particularity of the volume and location of ovarian tissue, the early symptoms of ovarian cancer are hidden, and there is a lack of highly sensitive and specific screening methods. Most patients have advanced metastasis, including abdominal metastasis, when they are diagnosed (Reid et al., 2017). Therefore, exploring the mechanism of ovarian cancer metastasis and finding early preventive measures are key to improving the survival rate and reducing mortality caused by ovarian cancer.

脂肪因子chemerin通过上调PD-L1的表达促进卵巢癌细胞增殖和迁移

目的:探究腹腔肿瘤微环境内脂肪因子趋化素(chemerin)与程序性死亡配体-1(PD-L1)是否存在关联,及其对卵巢癌细胞系HO8910细胞生物学功能的影响。
创新点:首次发现了chemerin可以上调卵巢癌细胞PD-L1的表达,促进肿瘤增殖和迁移。这对进一步研究免疫抑制剂在卵巢癌治疗中的应用、卵巢癌的早期诊断,以及血清和腹水中chemerin的检测具有一定的指导意义。此外,chemerin结合其他脂肪因子是否能成为卵巢癌诊断的标志物,需进一步的研究证实。
方法:使用酶联免疫吸附剂测定(ELISA)检测卵巢癌患者腹水和血清中chemerin的含量;使用免疫组化检测卵巢癌肿瘤组织中chemerin和PD-L1的表达;使用免疫印迹法检测卵巢癌组织中PD-L1的表达及在HO8910和HO891PM细胞中chemerin表达的差异;利用浓度分别为0、10、50和100ng/mL外源性chemerin刺激HO8910和HO8910PM细胞;使用水溶性四唑(WST)检测细胞增殖;使用划痕实验检测细胞迁移功能;利用鬼笔环肽荧光染色在共聚焦显微镜下观察PD-L1敲除前后的HO8910和HO8910PM的细胞骨架变化;使用免疫印迹法检测细胞骨架蛋白的表达情况。
结论:Chemerin可以上调卵巢癌细胞PD-L1的表达,对肿瘤增殖和迁移具有促进作用。

关键词组:卵巢癌;腹腔肿瘤微环境;脂肪因子;程序性死亡配体-1(PD-L1)

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]AlkadyMM, Abdel-MesseihPL, NosseirNM, 2018. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem, 37(3):313-319.

[2]BarbolinaMV, 2018. Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma. Cancers (Basel), 10(11):444.

[3]ChangCH, QiuJ, O'SullivanD, et al., 2015. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162(6):1229-1241.

[4]ChiJY, WuZH, ChoiCHJ, et al., 2018. Three-dimensional adipose tissue imaging reveals regional variation in beige fat biogenesis and PRDM16-dependent sympathetic neurite density. Cell Metab, 27(1):226-236.e3.

[5]ClarkCA, GuptaHB, SareddyG, et al., 2016. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res, 76(23):6964-6974.

[6]DrakesML, StiffPJ, 2018. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel), 10(9):302.

[7]El-SagheerG, GayyedM, AhmadA, et al., 2018. Expression of chemerin correlates with a poor prognosis in female breast cancer patients. Breast Cancer (Dove Med Press), 10:169-176.

[8]FreemanGJ, LongAJ, IwaiY, et al., 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192(7):1027-1034.

[9]Garcia-DiazA, ShinDS, MorenoBH, et al., 2017. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep, 19(6):1189-1201.

[10]GhallabNA, ShakerOG, 2017. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. Clin Oral Investig, 21(3):937-947.

[11]GhebehH, MohammedS, Al-OmairA, et al., 2006. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 8(3):190-198.

[12]GoralskiKB, JacksonAE, McKeownBT, et al., 2019. More than an adipokine: the complex roles of chemerin signaling in cancer. Int J Mol Sci, 20(19):4778.

[13]HamanishiJ, MandaiM, IwasakiM, et al., 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA, 104(9):3360-3365.

[14]HoY, WangSH, ChenYR, et al., 2019. Leptin-derived peptides block leptin-induced proliferation by reducing expression of pro-inflammatory genes in hepatocellular carcinoma cells. Food Chem Toxicol, 133:110808.

[15]HoffmannM, RakA, PtakA, 2018. Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol Lett, 291:61-69.

[16]IbrahimMM, 2010. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev, 11(1):11-18.

[17]IshikawaM, KitayamaJ, NagawaH, 2004. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res, 10(13):4325-4331.

[18]KumarJD, KandolaS, TiszlaviczL, et al., 2016. The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells. Br J Cancer, 114(10):1152-1159.

[19]KumarJD, AolymatI, TiszlaviczL, et al., 2019. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget, 10(2):98-112.

[20]LiJJ, YinHK, GuanDX, et al., 2018. Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. Br J Cancer, 118(10):1337-1348.

[21]MaineCJ, AzizNHA, ChatterjeeJ, et al., 2014. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother, 63(3):215-224.

[22]NiemanKM, KennyHA, PenickaCV, et al., 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 17(11):1498-1503.

[23]PachynskiRK, ZabelBA, KohrtHE, et al., 2012. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med, 209(8):1427-1435.

[24]PagetS, 1889. The distribution of secondary growths in cancer of the breast. The Lancet, 133(3412):571-573.

[25]ReidBM, PermuthJB, SellersTA, 2017. Epidemiology of ovarian cancer: a review. Cancer Biol Med, 14(1):9-32.

[26]RennierK, ShinWJ, KrugE, et al., 2020. Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via modulation of a novel CMKLR1-mediated signaling cascade. Clin Cancer Res, 26(18):5019-5035.

[27]ReverchonM, CornuauM, RameC, et al., 2012. Chemerin inhibits IGF-1-induced progesterone and estradiol secretion in human granulosa cells. Hum Reprod, 27(6):1790-1800.

[28]ShinWJ, PachynskiRK, 2018. Chemerin modulation of tumor growth: potential clinical applications in cancer. Discov Med, 26(141):31-37.

[29]SteeleCB, ThomasCC, HenleySJ, et al., 2017. Vital signs: trends in incidence of cancers associated with overweight and obesity—United States, 2005‒2014. MMWR Morb Mortal Wkly Rep, 66(39):1052-1058.

[30]TreeckO, BuechlerC, OrtmannO, 2019. Chemerin and cancer. Int J Mol Sci, 20(15):3750.

[31]WangCH, WuWKK, LiuXD, et al., 2014. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides, 51:131-138.

[32]WangZM, AguilarEG, LunaJI, et al., 2019. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med, 25(1):141-151.

[33]WiseHM, HermidaMA, LeslieNR, 2017. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond), 131(3):197-210.

[34]ZhangJ, JinHC, ZhuAK, et al., 2014. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides, 61:7-11.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE